PharmaTimes presents Alantra’s Fast 50 ranking of fastest growing, privately-owned pharmaceutical businesses in the UK
Manchester, UK, 17 May 2018: Concept Life Sciences (Concept), the integrated drug discovery, development and analytical services company, is delighted to have placed in the top 20 of Alantra’s Fast 50 for 2018, presented by The PharmaTimes. The annual ranking includes the year’s fastest growing, privately-owned pharmaceutical businesses in the UK, and recognises those who have undergone the most rapid revenue growth over the past two years. Those on the list are often found to be working closely with big pharma.
Concept placed 20th, with annualised revenue growth of 23 percent over the past two years. The Company represented ‘pharma outsourcing’, one of four distinct sub-sectors used to divide businesses included in the list, the other three being development; wholesale and supply (DWS); consulting; and pharmacy chains.
First published last year as the Catalyst Pharma Fast 50, PharmaTimes merged with Alantra, the global investment bank, for the 2018 list, with the ranking highlighting the most notable companies to the pharma industry, and the supplementary analysis looking in-depth at the most important trends affecting the industry right now.
Philip Payne, Chief Commercial Officer, Concept Life Sciences, said: “After a year of expansion across the business, in both integrated drug discovery and analytical services, we are very proud to have been included in the Fast 50 2018 list, and to have achieved an overall ranking of 20 across all four sub-sectors. We aim to maintain our momentum moving forward, whilst focusing on supporting our partners through provision of high quality service programs.”
The full listing, which was also published in the March 2018 edition of The Pharma Times, can be read here.